Abstract
Primary brain tumors including anaplastic astrocytomas and glioblastoma multiforme are difficult to treat because of their locally invasive nature and chemoradioresistance. Novel therapies are needed. One class of therapeutics is fusion proteins consisting of peptide toxins fused to brain tumor selective ligands. DAB389EGF is a fusion protein composed of the catalytic and translocation domains of diphtheria toxin fused via a His-Ala linker to human epidermal growth factor (EGF). DAB389EGF is selectively toxic to EGF receptor (EGFR) overexpressing cells. Close to half of all high-grade primary brain tumors have EGFR gene amplification and EGFR overexpression. With the use of convection-enhanced delivery (CED), DAB389EGF may be delivered locally at high concentrations to the brain tumor. CED would avoid many of the pharmacologic and toxicologic barriers which have limited effective use of this agent including rapid clearance from the circulation, high anti-diphtheria toxin antibody titers in the blood and toxicities to the liver and kidney. Both cell lines and animal models are available to assess the potential of this agent for brain tumor therapy. Since significant amounts of clinical grade DAB389EGF are available, some careful additional preclinical efficacy work should lead to testing of this agent in patients within the next few years.
Keywords: dab389egf, epidermal growth factor, refractory glioblastoma multiforme, fusion protein, astrocytomas multiforme
Current Pharmaceutical Biotechnology
Title: DAB389EGF Fusion Protein Therapy of Refractory Glioblastoma Multiforme
Volume: 4 Issue: 1
Author(s): Kimberley A. Cohen, TieFu Liu, Reid Bissonette, Raj K. Puri and Arthur E. Frankel
Affiliation:
Keywords: dab389egf, epidermal growth factor, refractory glioblastoma multiforme, fusion protein, astrocytomas multiforme
Abstract: Primary brain tumors including anaplastic astrocytomas and glioblastoma multiforme are difficult to treat because of their locally invasive nature and chemoradioresistance. Novel therapies are needed. One class of therapeutics is fusion proteins consisting of peptide toxins fused to brain tumor selective ligands. DAB389EGF is a fusion protein composed of the catalytic and translocation domains of diphtheria toxin fused via a His-Ala linker to human epidermal growth factor (EGF). DAB389EGF is selectively toxic to EGF receptor (EGFR) overexpressing cells. Close to half of all high-grade primary brain tumors have EGFR gene amplification and EGFR overexpression. With the use of convection-enhanced delivery (CED), DAB389EGF may be delivered locally at high concentrations to the brain tumor. CED would avoid many of the pharmacologic and toxicologic barriers which have limited effective use of this agent including rapid clearance from the circulation, high anti-diphtheria toxin antibody titers in the blood and toxicities to the liver and kidney. Both cell lines and animal models are available to assess the potential of this agent for brain tumor therapy. Since significant amounts of clinical grade DAB389EGF are available, some careful additional preclinical efficacy work should lead to testing of this agent in patients within the next few years.
Export Options
About this article
Cite this article as:
Cohen A. Kimberley, Liu TieFu, Bissonette Reid, Puri K. Raj and Frankel E. Arthur, DAB389EGF Fusion Protein Therapy of Refractory Glioblastoma Multiforme, Current Pharmaceutical Biotechnology 2003; 4 (1) . https://dx.doi.org/10.2174/1389201033378039
DOI https://dx.doi.org/10.2174/1389201033378039 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Myogenic Potential of Mesenchymal Stem Cells - the Case of Adhesive Fraction of Human Umbilical Cord Blood Cells
Current Stem Cell Research & Therapy Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition Circulating Tumor Stem Cells as Biomarkers for Cancer Progression
Recent Patents on Biomarkers Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Current Gene Therapy Advances in Nano Drugs for Cancer Chemotherapy
Current Cancer Drug Targets Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Mechano-Regulation of Alternative Splicing
Current Genomics Environmental Risk Assessment of Replication Competent Viral Vectors Applied in Clinical Trials: Potential Effects of Inserted Sequences
Current Gene Therapy Chemical Composition and Biological Activities of <i>Croton delpyi, Croton decalvatus</i> and <i>Croton caudatus</i>
The Natural Products Journal VEGF and HIF in Renal Cell Carcinogenesis
Recent Patents on Biomarkers Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Viral Vectors for Cancer Gene Therapy: Viral Dissemination and Tumor Targeting
Current Gene Therapy PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design Dendrimers: Nanosized Multifunctional Platform for Drug Delivery
Drug Delivery Letters HSV Amplicon Vectors for Cancer Therapy
Current Gene Therapy Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets